A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)

Abroad (travel likely)Recruiting

Conditions

Alagille Syndrome (ALGS) · Progressive Familial Intrahepatic Cholestasis (PFIC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Takeda selected site, Tokyo, Tokyo, Japan

Study leads

Study Director
Takeda

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)

Alagille Syndrome · Progressive Familial Intrahepatic Cholestasis

Abroad (travel likely)RecruitingPHASE4

Brussels, Belgium · Ghent, Belgium

Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

Alagille Syndrome · Progressive Familial Intrahepatic Cholestasis

Abroad (travel likely)Recruiting

Los Angeles, United States · Aurora, United States

A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

Alagille Syndrome

Abroad (travel likely)Recruiting

Los Angeles, United States · San Francisco, United States

Pediatric Evaluation and Registry for Liver Cholestasis in Canada

PFIC - Progressive Familial Intrahepatic Cholestasis · Alagille Syndrome (ALGS) · Cholestasis, Intrahepatic

Abroad (travel likely)Recruiting

Calgary, Canada · Edmonton, Canada